Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer
Overview the progress of liquid biopsy using circulating tumor cells (CTCs) and circulating cell-free tumor DNA (cfDNA) to detect and monitor breast cancer. Based on numerous research efforts, the potential value of CTCs and cfDNA in the clinical aspects of cancer has become clear. With the development of next-generation sequencing analysis and newly developed technologies, many technical issues have been resolved, making liquid biopsy widely used in clinical practice. They can be powerful tools for dynamic monitoring of tumor progression and therapeutic efficacy. In the field of breast cancer, liquid biopsy is a research hot spot in recent years, playing a key role in monitoring breast cancer metastasis, predicting disease recurrence and assessing clinical drug resistance. Liquid biopsy has the advantages of noninvasive, high sensitivity, high specificity and real-time dynamic monitoring. Still application is far from reality, but the research and application prospects of CTCs and cfDNA in breast cancer are still worth exploring and discovering. This article reviews the main techniques and applications of CTCs and cfDNA in breast cancer.
KeywordsCirculating tumor cells (CTCs) Circulating cell-free tumor DNA (ctDNA) Breast cancer Liquid biopsy
This work was supported by the National Basic Research Program of China (973 Program No. 2012CB933303), the National Natural Science Foundation of China (Program Nos. 81472751, 61271162, 61401442 and 61571428), the Shanghai Pujiang Program (No. 15PJ1409800), The Jiangsu Provincial Funds for Six Categories of Top Talents (Program No.WS-066) and The Research project of Jiangsu provincial health and Family Planning Commission (Program No. H201526).
Compliance with ethical standards
Conflict of interest
We have declared that no competing interests exist. The authors alone are responsible for the content and writing of the paper.
The study complies with the Declaration of Helsinki and was approved by the Ethics Committee of Affiliated Hospital of Nantong University, and all patients gave written informed consent.
- 11.L. N. CTC clusters more likely to cause metastasis. Cancer Discov. 2014;4:1246–7.Google Scholar
- 52.Wu WJ, Wang ZH, Wang Z, Deng YL, Shi QH. Fast isolation and ex vivo culture of circulating tumor cells from the peripheral blood of lung cancer patients. Hereditas. 2017;39:66–74.Google Scholar
- 54.Rothe F, Silva MJ, Venet D, Campbell C, Bradburry I, Rouas G et al. Circulating tumor DNA in HER2-amplified breast cancer: a translational research substudy of the NeoALTTO phase III trial. Clin Cancer Res. 2019.Google Scholar
- 57.Schramm A, Schochter F, Friedl TWP, de Gregorio N, Andergassen U, Alunni-Fabbroni M, et al. Prevalence of circulating tumor cells after adjuvant chemotherapy with or without anthracyclines in patients with HER2-negative, hormone receptor-positive early breast cancer. Clin Breast Cancer. 2017;17:279–85.CrossRefGoogle Scholar
- 60.Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Can Res. 2001;61:1659–65.Google Scholar
- 61.Canzoniero JV, Park BH. Use of cell free DNA in breast oncology. Biochem Biophys Acta. 2016;1865:266–74.Google Scholar
- 68.Korfhage C, Fricke E, Meier A. Parallel WGA and WTA for comparative genome and transcriptome NGS analysis using tiny cell numbers. Curr Protoc Mol Biol. 2015;111:7.19.1-8.Google Scholar
- 72.Lou QGJ. Research progresses of circulating tumor DNA. Chin J Cancer Biother 2016.Google Scholar
- 73.De Luca F, Rotunno G, Salvianti F, Galardi F, Pestrin M, Gabellini S, et al. Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer. Oncotarget. 2016;18:26107–19.Google Scholar
- 77.Thress KS, Brant R, Carr TH, Dearden S, Jenkins S, Brown H, et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer (Amsterdam, Netherlands). 2015;90:509–15.CrossRefGoogle Scholar
- 88.American Joint Committee on Cancer (2018) Updated breast chapter for 8th edition. Accessed 25 January 2018. https://cancerstaging.org/references-tools/deskreferences/Pages/Breast-Cancer-Staging.aspx.